EvolveImmune Therapeutics is at the forefront of developing a new class of precision cancer medicines aimed at enhancing patient outcomes through innovative therapeutic strategies. The company has identified and validated new pathways that are crucial for overcoming CD8 T cell exhaustion within the tumor microenvironment. By selectively regulating these mechanisms, EvolveImmune aims to drive effective and durable anti-cancer immunity, ultimately transforming the lives of cancer patients and their families.

The company's pipeline includes several promising biotherapeutics, such as EVOLVE-104, a first-in-class treatment targeting a variety of solid tumors, and EVOLVE-105, designed to improve outcomes for patients with relapsed or treatment-refractory B cell lymphoma. Additionally, EVOLVE-106 addresses unmet needs in specific solid tumor targets, while EVOLVE-101 focuses on a novel tumor antigen for B cell malignancies and certain myeloid malignancies. EvolveImmune's proprietary immunobiologics platform integrates T cell signaling to deliver sustained immune activation and targeted tumor cell destruction, enhancing the efficacy of their therapies while minimizing toxicity. The company is set to enter clinical trials with its first program in 2024, showcasing its commitment to advancing cancer treatment.

United States

At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies.

We are pioneers who rapidly translate discoveries into innovations and innovations into differentiated therapeutic solutions, to address the most significant unmet medical needs in oncology.

EvolveImmune Therapeutics

Company Details